Deutsche Bank
ARQT icon

Deutsche Bank’s Arcutis Biotherapeutics ARQT Stock Holding History

Deutsche Bank’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$11.9M Buy
450,999
+68,317
+18% +$1.79M ﹤0.01% 948
2026
Q2 		$10M Sell
382,682
-7,165
-2% -$167K ﹤0.01% 1059
2026
Q1 		$9.18M Sell
389,847
-540,355
-58% -$13.8M ﹤0.01% 1080
2025
Q4 		$27M Buy
930,202
+552,674
+146% +$14.1M 0.01% 800
2025
Q3 		$7.12M Buy
377,528
+10,113
+3% +$159K ﹤0.01% 1163
2025
Q2 		$5.15M Sell
367,415
-13,940
-4% -$195K ﹤0.01% 1225
2025
Q1 		$5.96M Sell
381,355
-6,181
-2% -$87.1K ﹤0.01% 1183
2024
Q4 		$5.4M Sell
387,536
-412,491
-52% -$4.52M ﹤0.01% 1296
2024
Q3 		$7.44M Sell
800,027
-1,081,998
-57% -$10.7M ﹤0.01% 1120
2024
Q2 		$17.5M Buy
1,882,025
+9,420
+0.5% +$85.2K 0.01% 849
2024
Q1 		$18.6M Buy
1,872,605
+478,195
+34% +$3.57M 0.01% 835
2023
Q4 		$4.5M Buy
1,394,410
+1,364,048
+4,493% +$3.71M ﹤0.01% 1295
2023
Q3 		$161K Buy
30,362
+3,655
+14% +$31.1K ﹤0.01% 2918
2023
Q2 		$255K Sell
26,707
-9,586
-26% -$106K ﹤0.01% 2750
2023
Q1 		$399K Buy
36,293
+11,121
+44% +$161K ﹤0.01% 2623
2022
Q4 		$373K Buy
25,172
+6,968
+38% +$122K ﹤0.01% 2602
2022
Q3 		$348K Buy
18,204
+555
+3% +$12.6K ﹤0.01% 2605
2022
Q2 		$376K Buy
17,649
+2,458
+16% +$50.4K ﹤0.01% 2769
2022
Q1 		$293K Sell
15,191
-1,778
-10% -$30.1K ﹤0.01% 3051
2021
Q4 		$352K Buy
16,969
+882
+5% +$17.6K ﹤0.01% 3044
2021
Q3 		$384K Sell
16,087
-1,946
-11% -$44.4K ﹤0.01% 3203
2021
Q2 		$492K Buy
18,033
+1,428
+9% +$40.2K ﹤0.01% 3228
2021
Q1 		$480K Sell
16,605
-99,330
-86% -$3.1M ﹤0.01% 3130
2020
Q4 		$3.26M Buy
115,935
+106,120
+1,081% +$2.6M ﹤0.01% 1603
2020
Q3 		$288K Buy
9,815
+5,090
+108% +$136K ﹤0.01% 2990
2020
Q2 		$143K Buy
4,725
+1,067
+29% +$30.8K ﹤0.01% 3285
2020
Q1 		$109K Buy
+3,658
New +$98.3K ﹤0.01% 3207

Other funds holding ARQT

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $229B AUM 33.35% 1-Year Est. Return
GW&K Investment Management
GW&K Investment Management Boston, Massachusetts $11.8B AUM 29.45% 1-Year Est. Return

Deutsche Bank's ARQT Position: Q3 2026 in Review

Deutsche Bank increased its Arcutis Biotherapeutics (ARQT) stake by 18% in Q3 2026, buying an estimated $1.79M and bringing the position to 450,999 shares worth $11.9M. The position accounts for ﹤0.01% of the portfolio, ranked #948.

Deutsche Bank first reported a position in ARQT in Q1 2020 and has held it in 27 quarters since. The position peaked at $27M in Q4 2025. 212 funds tracked by Wall St. Rank hold ARQT as of Q3 2026.

  • Deutsche Bank held 450,999 shares of Arcutis Biotherapeutics worth $11.9M as of Q3 2026.
  • Deutsche Bank bought 68,317 Arcutis Biotherapeutics shares in Q3 2026, an estimated $1.79M.
  • Arcutis Biotherapeutics made up ﹤0.01% of Deutsche Bank's portfolio in Q3 2026, its #948 holding.
  • Deutsche Bank first reported a position in Arcutis Biotherapeutics in Q1 2020 and has held it in 27 quarters since.
  • Deutsche Bank's Arcutis Biotherapeutics position peaked at $27M in Q4 2025.
  • 212 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q3 2026.

Based on Deutsche Bank's 13F filing for Q3 2026, filed 6 Nov 2026.